跳至主要内容
临床试验/CTRI/2017/02/007857
CTRI/2017/02/007857已完成4 期

An active surveillance to monitor the real world safety in Indian patients prescribed nintedanib for the treatment of locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy

Boehringer Ingelheim India Pvt Ltd0 个研究点目标入组 28 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
28

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • 1. Patients =18 years of age with locally advanced and/or metastatic NSCLC of stage IIIB or IV, or recurrent NSCLC and adenocarcinoma histology after relapse or failure of first line of chemotherapy who are newly prescribed nintedanib according to the package insert.
  • 2. Willing to provide the informed consent
  • 3. Patients in whom further visit/contact is possible during the planned period of active surveillance
  • 4. Patients in whom information mentioned in the section 9.2.2.2 of the protocol is available

排除标准

  • 1. Patients who have taken nintedanib before participation in the study
  • 2. Patients who are positive for EGFR mutation
  • 3. Patients who are positive for ALK rearrangements
  • 4. Patients who are participating in a clinical trial

研究者

发起方
Boehringer Ingelheim India Pvt Ltd

相似试验